Cantitate/Preț
Produs

Innovation, Commercialization, and Start-Ups in Life Sciences

Autor James F. Jordan
en Limba Engleză Hardback – 5 noi 2014
Innovation is the translation of a new method, idea, or product into reality and profit. It is a process of connected steps that accumulates into your brand or reputation. However, there can be many pitfalls and wrong turns on the road to realizing this goal. Innovation, Commercialization, and Start-Ups in Life Sciences details the methodologies necessary to create a successful life sciences start-up from initiation to exit. You will gain an appreciation for the necessary data, partnership, and skills to be acquired and the constituencies that must be satisfied along the way.
The book examines how life sciences start-ups can create an exit for their investors by recognizing that a liquidity event is not consummated without due diligence. Due diligence is bigger than validating accounting transactions. It ensures the company is solving an important customer problem, demonstrating sales access, and making sure that intellectual property is impervious to competitive advancement. The due diligence process supports the telling of a compelling story to customers, investors, regulators, and acquirers.
Written by an expert who has worked with more than 200 life sciences start-ups during the past decade, the book discusses specific processes and investor milestones that must be navigated to align customer, funder, and acquirer needs. It examines these processes from the perspective of marketing value through a focus on the needs of individual constituents—investors, regulators, customers, and exit candidates. The book presents data and analytical processes articulating the fundable milestones for angel and venture capital. It gives you the tools needed to create branding for public investors and more.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 45596 lei  6-8 săpt.
  CRC Press – 28 sep 2021 45596 lei  6-8 săpt.
Hardback (2) 67240 lei  6-8 săpt.
  CRC Press – 5 noi 2014 67240 lei  6-8 săpt.
  CRC Press – 28 sep 2021 110824 lei  6-8 săpt.

Preț: 67240 lei

Preț vechi: 79106 lei
-15% Nou

Puncte Express: 1009

Preț estimativ în valută:
12869 13399$ 10875£

Carte tipărită la comandă

Livrare economică 11-25 martie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781482210125
ISBN-10: 1482210126
Pagini: 256
Ilustrații: 29 black & white illustrations, 7 black & white tables
Dimensiuni: 156 x 234 x 18 mm
Greutate: 0.52 kg
Ediția:1
Editura: CRC Press
Colecția CRC Press

Public țintă

Academic and Professional Practice & Development

Cuprins

Part 1 – Innovation is a Process of Connected Steps. Investment Uses a Translation Process to Deliver Innovation. Investment is Critical to a Nation’s Prosperity. The Journey of Innovation Begins With Investment. The U.S. Helps Small Companies Develop Technology. Commercialization is Primarily Executed Through Two Organizational Types. Part 2 – Investment Must Be Connected to Exit. Angels and Venture Capitalists Invest in Commercialization. Create Liquidity For Your Investors. A Liquidity Event is Not Consummated Without Due Diligence. Due Diligence Reputation is a Critical Business Process. Part 3 – Align With the Industry Norms. Find the Industry Norms. Solve an Important Customer Problem. Demonstrate the Ability to Access the Sales Channel. Gather Domain-Experienced Personnel to Reduce Risk. Determine Acquirers’ Strategic Future and Purchase Triggers. Align Investor’s Fundable Milestones and Acquirer’s Exit Points. Create an IP Pyramid for Impervious Positioning. Part 4 – A Startup Must Tell a Compelling Story. Address Your Story to the Needs of All Constituencies. Deliver to Your Plan. Tell a Compelling Story With the Investor Pitch. Continuously Improve Your Message With the Plan-Do-Check-Act Cycle.

Notă biografică

Jim Jordan, a Distinguished Service Professor of Healthcare & Biotechnology Management and Senior Director of Healthcare and Biotechnology Programs at Carnegie Mellon University’s Heinz College, serves as the Chief Investment Officer of the Pittsburgh Life Sciences Greenhouse, a public-private economic and venture fund owned by Carnegie Mellon University and the University of Pittsburgh.
As an accomplished Fortune 20-level executive with companies such as Boston Scientific, Johnson & Johnson and McKesson, Jim has leveraged his experience in several startup ventures and is active on multiple Boards of Directors. Through the Pittsburgh Life Sciences Greenhouse, he has applied his 25 years of experience in industry, consulting and academia to work with over 400 life science startup companies, with direct investment in 75 of them.

Recenzii

"So how do you get more new innovative technology to market? Well, you take risks for sure, but you have to have a process for churning the evolution of technology and turning concepts in the minds of researchers and entrepreneurs into commercialized products in the market. The contents of this book will not only do that for the reader, but the book will also show the pitfalls to avoid along the way. Not every good idea is able to get to market. … And what causes innovators to fail? The answers to these and other important questions are addressed in the book."
—From the Foreword by John W. Manzetti, President and CEO, Pittsburgh Life Sciences Greenhouse, Founder, Managing Director, PLSG Accelerator Fund
"This book, and the approach the author describes in it, is based in extensive real-life experience. The author gives the reader the theory behind innovation and commercialization, but then adds the application details only an experienced professional can deliver. ... I like the fact that the book is driven from the perspective of the investor versus the technologist or policy analyst. ... I think the author has written a very useful guide that is clear and compelling."
—William Donaldson, Christopher Newport University, Newport News, Virginia, USA 

Descriere

This book specifically provides the reader with the methodologies necessary to create a successful life sciences start-up from initiation to exit. The readers gain an appreciation for the necessary data, partnership, and skills to be acquired and the constituencies that must be satisfied, along the way. It presents data and analytical processes articulating the fundable milestones for angel and venture capital. It also provides tools for creating branding for public investors and more.